These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245 [TBL] [Abstract][Full Text] [Related]
47. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Plano F; Corsale AM; Gigliotta E; Camarda G; Vullo C; Di Simone M; Shekarkar Azgomi M; Speciale M; Carlisi M; Caccamo N; Dieli F; Meraviglia S; Siragusa S; Botta C Hematol Rep; 2023 Jan; 15(1):23-49. PubMed ID: 36648882 [TBL] [Abstract][Full Text] [Related]
48. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290 [TBL] [Abstract][Full Text] [Related]
49. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma. Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090 [TBL] [Abstract][Full Text] [Related]
50. Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. Manier S; Salem KZ; Liu D; Ghobrial IM Am Soc Clin Oncol Educ Book; 2016; 35():e400-6. PubMed ID: 27249747 [TBL] [Abstract][Full Text] [Related]
51. Novel therapeutic targets in multiple myeloma. Cottini F; Anderson K Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582 [TBL] [Abstract][Full Text] [Related]
52. Towards Stratified Medicine in Plasma Cell Myeloma. Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669 [TBL] [Abstract][Full Text] [Related]
53. Recent advances in understanding multiple myeloma. Hari P Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):267-271. PubMed ID: 28633036 [TBL] [Abstract][Full Text] [Related]
54. Pathogenesis of myeloma. Anderson KC; Carrasco RD Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519 [TBL] [Abstract][Full Text] [Related]
55. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. Dezube BJ; Aboulafia DM; Pantanowitz L AIDS Read; 2004 Jul; 14(7):372-4, 377-9. PubMed ID: 15282866 [TBL] [Abstract][Full Text] [Related]
56. Treatment of high-risk smoldering myeloma. Korde N Semin Oncol; 2016 Dec; 43(6):695-696. PubMed ID: 28061988 [TBL] [Abstract][Full Text] [Related]
57. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison S; Mollee P; Roberts A; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM Intern Med J; 2015 Mar; 45(3):335-43. PubMed ID: 25735577 [TBL] [Abstract][Full Text] [Related]
58. Targeting the Microenvironment for Treating Multiple Myeloma. Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976 [TBL] [Abstract][Full Text] [Related]
59. Emerging biological insights and novel treatment strategies in multiple myeloma. Gentile M; Recchia AG; Mazzone C; Morabito F Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042 [TBL] [Abstract][Full Text] [Related]